FORT WASHINGTON, Pa.--(BUSINESS WIRE)--Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced the company’s novel, clinical-stage renin inhibitor, VTP-27999, has been recognized by Windhover as a “Top 10 Project to Watch” in the cardiovascular/metabolic disease category. Top 10 projects in four therapeutic areas will be highlighted at Windhover’s annual Therapeutic Area Partnerships meeting in Boston, MA. Jeffrey Hatfield, Vitae’s Chief Executive Officer, will present information on VTP-27999 at the meeting on November 18, 2009.
